Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 475.75 INR 0.39%
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

Cipla Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipla Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cipla Ltd
NSE:CIPLA
Cash from Operating Activities
â‚ą45B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Operating Activities
â‚ą34.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Operating Activities
â‚ą127.2B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Cash from Operating Activities
â‚ą31.1B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Operating Activities
â‚ą34.1B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash from Operating Activities
â‚ą21.5B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipla Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
1 165.02 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Cipla Ltd's Cash from Operating Activities?
Cash from Operating Activities
45B INR

Based on the financial report for Sep 30, 2024, Cipla Ltd's Cash from Operating Activities amounts to 45B INR.

What is Cipla Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
7%

Over the last year, the Cash from Operating Activities growth was 19%. The average annual Cash from Operating Activities growth rates for Cipla Ltd have been 7% over the past three years .

Back to Top